Differential immunoreactivity of plasma glucagon components in man: Studies with different glucagon antibodies

David Soybel, Jonathan Jaspan, Kenneth Polonsky, I. Goldberg, Elliott Rayfield, Howard Tager

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

To evaluate the relationship between glucagon antibody antigenic determinants and selective reactivity with plasma void volume (Vo) and lower molecular weight immunoreactive glucagon (IRG) components, we studied plasma IRG levels and molecular profiles in normal subjects and patients with disturbances in plasma glucagon levels using three glucagon antibodies, 30K and P7 raised against the whole peptide and antibody X4 raised against the C-terminal tryptic fragment of glucagon. In normal subjects and pancreatectomized patients, plasma IRG levels were 2- to 3-fold higher with the C-terminusdirected antibody X4 than with either 30K or P7, but in glucagonoma and uremic patients, this discrepancy was smaller. Gel filtration analysis revealed that these antibodies reacted identically with 3500 mol wt IRG and 9000 mol wt IRG in normal, glucagonoma, pancreatectomized, and uremic plasma. Relative immunoreactivity of Vo IRG was approximately 5:2:1 with antibodies X4, 30K, and P7, respectively. In two subjects with unexplained hyperglucagonemia, recovery of IRG was entirely in the Vo, with antiserum X4 reacting one third as well as 30K and P7 not reacting at all. Furthermore, this material did not dilute out in parallel to glucagon standard. These data indicate differential immunoreactivity of the high molecular weight circulating IRG component, with a series of three glucagon antibodies reacting similarly with all other plasma IRG fractions, and suggest that Vo IRG material in plasma is predominantly the result of an immunologically cross-reacting peptide sequence in a plasma protein. The selective immunoreactivity of this component with different antibodies has important implications for the glucagon RIA and may have some bearing on other immunoassays as well.

Original languageEnglish (US)
Pages (from-to)612-618
Number of pages7
JournalJournal of Clinical Endocrinology and Metabolism
Volume56
Issue number3
DOIs
StatePublished - Jan 1 1983

Fingerprint

Glucagon
Plasmas
Antibodies
Glucagonoma
Bearings (structural)
Molecular Weight
Molecular weight
Peptides
Plasma Volume
Immunoassay
Gel Chromatography
Blood Proteins
Immune Sera
Epitopes

All Science Journal Classification (ASJC) codes

  • Endocrinology, Diabetes and Metabolism
  • Biochemistry
  • Endocrinology
  • Clinical Biochemistry
  • Biochemistry, medical

Cite this

Soybel, David ; Jaspan, Jonathan ; Polonsky, Kenneth ; Goldberg, I. ; Rayfield, Elliott ; Tager, Howard. / Differential immunoreactivity of plasma glucagon components in man : Studies with different glucagon antibodies. In: Journal of Clinical Endocrinology and Metabolism. 1983 ; Vol. 56, No. 3. pp. 612-618.
@article{e02ab5a713164b2b8be96b00b269ff61,
title = "Differential immunoreactivity of plasma glucagon components in man: Studies with different glucagon antibodies",
abstract = "To evaluate the relationship between glucagon antibody antigenic determinants and selective reactivity with plasma void volume (Vo) and lower molecular weight immunoreactive glucagon (IRG) components, we studied plasma IRG levels and molecular profiles in normal subjects and patients with disturbances in plasma glucagon levels using three glucagon antibodies, 30K and P7 raised against the whole peptide and antibody X4 raised against the C-terminal tryptic fragment of glucagon. In normal subjects and pancreatectomized patients, plasma IRG levels were 2- to 3-fold higher with the C-terminusdirected antibody X4 than with either 30K or P7, but in glucagonoma and uremic patients, this discrepancy was smaller. Gel filtration analysis revealed that these antibodies reacted identically with 3500 mol wt IRG and 9000 mol wt IRG in normal, glucagonoma, pancreatectomized, and uremic plasma. Relative immunoreactivity of Vo IRG was approximately 5:2:1 with antibodies X4, 30K, and P7, respectively. In two subjects with unexplained hyperglucagonemia, recovery of IRG was entirely in the Vo, with antiserum X4 reacting one third as well as 30K and P7 not reacting at all. Furthermore, this material did not dilute out in parallel to glucagon standard. These data indicate differential immunoreactivity of the high molecular weight circulating IRG component, with a series of three glucagon antibodies reacting similarly with all other plasma IRG fractions, and suggest that Vo IRG material in plasma is predominantly the result of an immunologically cross-reacting peptide sequence in a plasma protein. The selective immunoreactivity of this component with different antibodies has important implications for the glucagon RIA and may have some bearing on other immunoassays as well.",
author = "David Soybel and Jonathan Jaspan and Kenneth Polonsky and I. Goldberg and Elliott Rayfield and Howard Tager",
year = "1983",
month = "1",
day = "1",
doi = "10.1210/jcem-56-3-612",
language = "English (US)",
volume = "56",
pages = "612--618",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "3",

}

Differential immunoreactivity of plasma glucagon components in man : Studies with different glucagon antibodies. / Soybel, David; Jaspan, Jonathan; Polonsky, Kenneth; Goldberg, I.; Rayfield, Elliott; Tager, Howard.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 56, No. 3, 01.01.1983, p. 612-618.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Differential immunoreactivity of plasma glucagon components in man

T2 - Studies with different glucagon antibodies

AU - Soybel, David

AU - Jaspan, Jonathan

AU - Polonsky, Kenneth

AU - Goldberg, I.

AU - Rayfield, Elliott

AU - Tager, Howard

PY - 1983/1/1

Y1 - 1983/1/1

N2 - To evaluate the relationship between glucagon antibody antigenic determinants and selective reactivity with plasma void volume (Vo) and lower molecular weight immunoreactive glucagon (IRG) components, we studied plasma IRG levels and molecular profiles in normal subjects and patients with disturbances in plasma glucagon levels using three glucagon antibodies, 30K and P7 raised against the whole peptide and antibody X4 raised against the C-terminal tryptic fragment of glucagon. In normal subjects and pancreatectomized patients, plasma IRG levels were 2- to 3-fold higher with the C-terminusdirected antibody X4 than with either 30K or P7, but in glucagonoma and uremic patients, this discrepancy was smaller. Gel filtration analysis revealed that these antibodies reacted identically with 3500 mol wt IRG and 9000 mol wt IRG in normal, glucagonoma, pancreatectomized, and uremic plasma. Relative immunoreactivity of Vo IRG was approximately 5:2:1 with antibodies X4, 30K, and P7, respectively. In two subjects with unexplained hyperglucagonemia, recovery of IRG was entirely in the Vo, with antiserum X4 reacting one third as well as 30K and P7 not reacting at all. Furthermore, this material did not dilute out in parallel to glucagon standard. These data indicate differential immunoreactivity of the high molecular weight circulating IRG component, with a series of three glucagon antibodies reacting similarly with all other plasma IRG fractions, and suggest that Vo IRG material in plasma is predominantly the result of an immunologically cross-reacting peptide sequence in a plasma protein. The selective immunoreactivity of this component with different antibodies has important implications for the glucagon RIA and may have some bearing on other immunoassays as well.

AB - To evaluate the relationship between glucagon antibody antigenic determinants and selective reactivity with plasma void volume (Vo) and lower molecular weight immunoreactive glucagon (IRG) components, we studied plasma IRG levels and molecular profiles in normal subjects and patients with disturbances in plasma glucagon levels using three glucagon antibodies, 30K and P7 raised against the whole peptide and antibody X4 raised against the C-terminal tryptic fragment of glucagon. In normal subjects and pancreatectomized patients, plasma IRG levels were 2- to 3-fold higher with the C-terminusdirected antibody X4 than with either 30K or P7, but in glucagonoma and uremic patients, this discrepancy was smaller. Gel filtration analysis revealed that these antibodies reacted identically with 3500 mol wt IRG and 9000 mol wt IRG in normal, glucagonoma, pancreatectomized, and uremic plasma. Relative immunoreactivity of Vo IRG was approximately 5:2:1 with antibodies X4, 30K, and P7, respectively. In two subjects with unexplained hyperglucagonemia, recovery of IRG was entirely in the Vo, with antiserum X4 reacting one third as well as 30K and P7 not reacting at all. Furthermore, this material did not dilute out in parallel to glucagon standard. These data indicate differential immunoreactivity of the high molecular weight circulating IRG component, with a series of three glucagon antibodies reacting similarly with all other plasma IRG fractions, and suggest that Vo IRG material in plasma is predominantly the result of an immunologically cross-reacting peptide sequence in a plasma protein. The selective immunoreactivity of this component with different antibodies has important implications for the glucagon RIA and may have some bearing on other immunoassays as well.

UR - http://www.scopus.com/inward/record.url?scp=0020696979&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020696979&partnerID=8YFLogxK

U2 - 10.1210/jcem-56-3-612

DO - 10.1210/jcem-56-3-612

M3 - Article

C2 - 6185527

AN - SCOPUS:0020696979

VL - 56

SP - 612

EP - 618

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 3

ER -